Skip to main content
. 2023 May 12;11:1133959. doi: 10.3389/fpubh.2023.1133959

Table 2.

Yearly breakdown of the healthcare economic impact of the anti-PD-(L)1 class.

2021 2022 2023 2024+ Average
Economic impact (€) 89,930,968 110,970,853 124,435,262 80,110,138 108,445,694

PD-1, programmed cell death protein-1; PD-L1, programmed cell death-ligand 1.